Prognostic Value of Peroxiredoxin-1 Expression in Patients with Solid Tumors: a Meta-Analysis of Cohort Study

Abstract

Background and Aim. Peroxiredoxin-1 (PRDX1) has been reported to be abnormally expressed in various malignancies. However, the prognostic role of PRDX1 in human solid tumors remains controversial. We performed this meta-analysis to accurately assess the prognostic significance of PRDX1 protein in patients with solid tumors. Methods. We comprehensively searched electronic databases, namely, PubMed, Web of Science, EMBASE, Chinese National Knowledge Infrastructure (CNKI), and WanFang databases up to December 2019. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated to evaluate the association between PRDX1 protein expression and the survival of patients with solid tumors. Odds ratios (ORs) with 95% CIs were pooled to estimate the correlation between PRDX1 protein expression and clinicopathologic characteristics in the patients. Results. Seventeen cohort studies that involved 2,858 patients were included in this meta-analysis. The pooled results indicated that positive PRDX1 expression was related to poor overall survival ( $\text{HR}=1.68$ , 95% CI: 1.24-2.27, $P=0.001$ ) and disease-free survival ( $\text{HR}=1.88$ , 95% CI: 1.31-2.70, $P=0.001$ ). In addition, high PRDX1 expression was associated with large tumor size ( $\text{OR}=1.69$ , 95% CI: 1.07-2.68, $P=0.025$ ), advanced TNM stage ( $\text{OR}=2.26$ , 95% CI: 1.24-4.13, $P=0.008$ ), and poor tumor differentiation ( $\text{OR}=0.59$ , 95% CI: 0.44-0.81, $P=0.001$ ). Conclusions. PRDX1 overexpression is associated with poor outcomes of cancers and may serve as a prognostic biomarker for malignant patients. Hence, PRDX1 could be a new target for antitumor therapy.